Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Neuroblastoma | Research article

Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma

Authors: Rebeca Burgos-Panadero, Inmaculada Noguera, Adela Cañete, Samuel Navarro, Rosa Noguera

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Vitronectin is a multifunctional glycoprotein known in several human tumors for its adhesive role in processes such as cell growth, angiogenesis and metastasis. In this study, we examined vitronectin expression in neuroblastoma to investigate whether this molecule takes part in cell-cell or cell-extracellular matrix interactions that may confer mechanical properties to promote tumor aggressiveness.

Methods

We used immunohistochemistry and image analysis tools to characterize vitronectin expression and to test its prognostic value in 91 neuroblastoma patients. To better understand the effect of vitronectin, we studied its in vitro expression using commercial neuroblastoma cell lines and in vivo using intra-adrenal gland xenograft models by immunohistochemistry.

Results

Digital image analysis allowed us to associate vitronectin staining intensity and location discriminating between territorial vitronectin and interterritorial vitronectin expression patterns. High territorial vitronectin expression (strong staining associated with pericellular and intracellular location) was present in tumors from patients with metastatic undifferentiating neuroblastoma, that were MYCN amplified, 11q deleted or with segmental chromosomal profiles, in the high-risk stratification group and with high genetic instability. In vitro studies confirmed that vitronectin is expressed in tumor cells as small cytoplasmic dot drops. In vivo experiments revealed tumor cells with high and dense cytoplasmic vitronectin expression.

Conclusions

These findings highlight the relevance of vitronectin in neuroblastoma tumor biology and suggest its potential as a future therapeutic target in neuroblastoma.
Appendix
Available only for authorised users
Literature
1.
Xiong G, Xu R. Function of cancer cell-derived extracellular matrix in tumor progression. J Cancer Metastasis Treat. 2016;2:357–64.CrossRef
2.
Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15(12):1243–53.CrossRef
3.
Wells RG. The role of matrix stiffness in regulating cell behavior. Hepatology. 2008;47(4):1394–400.CrossRef
4.
Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer. 2011;11(7):512–22.CrossRef
5.
Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med. 2011;15(5):1013–31.CrossRef
6.
Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis. Breast. 2013;22(Suppl 2):S66–72.CrossRef
7.
Vincent T, Mechti N. Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leuk Lymphoma. 2005;46(6):803–11.CrossRef
8.
Lin HH, Lin HK, Lin IH, Chiou YW, Chen HW, Liu CY, et al. Mechanical phenotype of cancer cells: cell softening and loss of stiffness sensing. Oncotarget. 2015;6(25):20946–58.PubMedPubMedCentral
9.
Preissner KT. Structure and biological role of vitronectin. Annu Rev Cell Biol. 1991;7:275–310.CrossRef
10.
Schvartz I, Seger D, Shaltiel S. Vitronectin. Int J Biochem Cell Biol. 1999;31(5):539–44.CrossRef
11.
Seiffert D. Constitutive and regulated expression of vitronectin. Histol Histopathol. 1997;12(3):787–97.PubMed
12.
Gladson CL, Dennis C, Rotolo TC, Kelly DR, Grammer JR. Vitronectin expression in differentiating neuroblastic tumors: integrin alpha v beta 5 mediates vitronectin-dependent adhesion of retinoic-acid-differentiated neuroblastoma cells. Am J Pathol. 1997;150(5):1631–46.PubMedPubMedCentral
13.
Dimova T, Georgieva R, Petlov D, Lazarova S. Comparative study on the expression of fibronectin, vitronectin, α5β1, β3 and αν integrins in goat and pig adrenal glands. Comptes rendus de l'Academie bulgare des Sciences. 2005;12:1457–62.
14.
Edwards S, Lalor PF, Tuncer C, Adams DH. Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner. Br J Cancer. 2006;95(11):1545–54.CrossRef
15.
Yasumitsu H, Seo N, Misugi E, Morita H, Miyazaki K, Umeda M. Vitronectin secretion by hepatic and non-hepatic human cancer cells. In Vitro Cell Dev Biol Anim. 1993;29A(5):403–7.CrossRef
16.
Preissner KT. The role of vitronectin as multifunctional regulator in the hemostatic and immune systems. Blut. 1989;59(5):419–31.CrossRef
17.
Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol. 2007;177(5):927–39.CrossRef
18.
Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest. 1991;88(6):1924–32.CrossRef
19.
Schneider G, Bryndza E, Poniewierska-Baran A, Serwin K, Suszynska M, Sellers ZP, et al. Evidence that vitronectin is a potent migration-enhancing factor for cancer cells chaperoned by fibrinogen: a novel view of the metastasis of cancer cells to low-fibrinogen lymphatics and body cavities. Oncotarget. 2016;7(43):69829–43.CrossRef
20.
Shi K, Lan RL, Tao X, Wu CY, Hong HF, Lin JH. Vitronectin significantly influences prognosis in osteosarcoma. Int J Clin Exp Pathol. 2015;8(9):11364–71.PubMedPubMedCentral
21.
Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13(6):397–411.CrossRef
22.
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27(2):289–97.CrossRef
23.
Tadeo I, Berbegall A, Castel V, García-Miguel P, Callaghan R, Påhlman S, et al. Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort. Br J Cancer. 2016;115(4):480–9.CrossRef
24.
25.
Tadeo I, Bueno G, Berbegall A, Fernández-Carrobles M, Castel V, García-Rojo M, et al. Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors. Oncotarget. 2016;7(15):19935–47.CrossRef
26.
Tadeo I, Gamero-Sandemetrio E, Berbegall AP, Navarro S, Cañete A, Noguera R. 1p36 deletion results in a decrease in glycosaminoglycans which is associated with aggressiveness in neuroblastic tumors. Histol Histopathol. 2018;33:487–95.PubMed
27.
Erdreich-Epstein A, Shimada H, Groshen S, Liu M, Metelitsa LS, Kim KS, et al. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 2000;60(3):712–21.PubMed
28.
Ambros IM, Brunner C, Abbasi R, Frech C, Ambros PF. Ultra-high density SNParray in neuroblastoma molecular diagnostics. Front Oncol. 2014;4:202.CrossRef
29.
Lavorato-Rocha AM, Akagi EM, de Melo Maia B, Rodrigues IS, Botelho MC, Marchi FA, et al. An integrative approach uncovers biomarkers that associate with clinically relevant disease outcomes in vulvar carcinoma. Mol Cancer Res. 2016;14(8):720–9.CrossRef
30.
Niu Y, Zhang L, Bi X, Yuan S, Chen P. Evaluation of Vitronectin expression in prostate Cancer and the clinical significance of the Association of Vitronectin Expression with prostate specific antigen in detecting prostate Cancer. Urol J. 2016;13(1):2527–32.PubMed
31.
Ortega-Martinez I, Gardeazabal J, Erramuzpe A, Sanchez-Diez A, Cortes J, Garcia-Vazquez MD, et al. Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early-stage melanoma. Int J Cancer. 2016;139(7):1598–607.CrossRef
32.
Li P, Gao Y, Ji Z, Zhang X, Xu Q, Li G, et al. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma. J Pediatr Surg. 2004;39(10):1512–9.CrossRef
33.
Nast CC, Lemley KV, Hodgin JB, Bagnasco S, Avila-Casado C, Hewitt SM, et al. Morphology in the digital age: integrating high-resolution description of structural alterations with phenotypes and genotypes. Semin Nephrol. 2015;35(3):266–78.CrossRef
34.
Mulrane L, Rexhepaj E, Penney S, Callanan JJ, Gallagher WM. Automated image analysis in histopathology: a valuable tool in medical diagnostics. Expert Rev Mol Diagn. 2008;8(6):707–25.CrossRef
35.
Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008;118(4):1367–79.CrossRef
36.
Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci. 1995;108 ( Pt 3:947–56.PubMed
37.
Pirazzoli V, Ferraris GM, Sidenius N. Direct evidence of the importance of vitronectin and its interaction with the urokinase receptor in tumor growth. Blood. 2013;121(12):2316–23.CrossRef
38.
Chang C, Lee SO, Yeh S, Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2014;33(25):3225–34.CrossRef
39.
nGraham DM, Burridge K. Mechanotransduction and nuclear function. Curr Opin Cell Biol. 2016;40:98–105.CrossRef
40.
Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006;8(2):R20.CrossRef
41.
Mauro CD, Pesapane A, Formisano L, Rosa R, D'Amato V, Ciciola P, et al. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci Rep. 2017;7(1):9388.CrossRef
42.
Harbeck N, Kruger A, Sinz S, Kates RE, Thomssen C, Schmitt M, et al. Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor. Onkologie. 2001;24(3):238–44.PubMed
43.
Li R, Luo M, Ren M, Chen N, Xia J, Deng X, et al. Vitronectin regulation of vascular endothelial growth factor-mediated angiogenesis. J Vasc Res. 2014;51(2):110–7.CrossRef
44.
Holle AW, Young JL, Spatz JP. In vitro cancer cell-ECM interactions inform in vivo cancer treatment. Adv Drug Deliv Rev. 2016;97:270–9.CrossRef
45.
Zhang Y, Yang M, Ji Q, Fan D, Peng H, Yang C, et al. Anoikis induction and metastasis suppression by a new integrin alphavbeta3 inhibitor in human melanoma cell line M21. Investig New Drugs [Internet. 2011;29(4):666–73.CrossRef
46.
Montuori N, Pesapane A, Rossi FW, Giudice V, De Paulis A, Selleri C, et al. Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer. Transl Med UniSa. 2016;15:15–21.PubMedPubMedCentral
47.
Noh H, Hong S, Huang S. Role of urokinase receptor in tumor progression and development. Theranostics. 2013;3(7):487–95.CrossRef
48.
Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11(1):23–36.CrossRef
49.
Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, et al. An anti-Urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate Cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia. 2010;10:778–88.CrossRef
50.
Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57(1):25–40.CrossRef
51.
Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM, et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell. 2008;14(4):324–34.CrossRef
52.
Masuda T, Hattori N, Senoo T, Akita S, Ishikawa N, Fujitaka K, et al. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis. Mol Cancer Ther. 2013;12(11):2378–88.CrossRef
53.
Placencio VR, Ichimura A, Miyata T, DeClerck YA. Small molecule inhibitors of plasminogen activator Inhibitor-1 elicit anti-tumorigenic and anti-Angiogenic activity. PLoS One. 2015;10(7):e0133786.CrossRef
Metadata
Title
Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma
Authors
Rebeca Burgos-Panadero
Inmaculada Noguera
Adela Cañete
Samuel Navarro
Rosa Noguera
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5693-2

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Case report

B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review

Study protocol

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Correction

Correction to: Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations

Research article

Multiband mucosectomy versus endoscopic submucosal dissection and endoscopic submucosal excavation for GI submucosal tumors: short and long term follow-up

Research article

Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma

Research article

Effect of topical microporous polysaccharide hemospheres on the duration and amount of fluid drainage following mastectomy: a prospective randomized clinical trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits